Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.82 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.82 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.82 |
| ▸ | EP300 | Q09472 | 4/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.44 |
| ▸ | TOP1 | P11387 | 2/20 | 0.42 |
| ▸ | PRKCA | P17252 | 3/20 | 0.41 |
| ▸ | HRAS | P01112 | 3/20 | 0.40 |
| ▸ | ESR1 | P03372 | 3/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL805239 | 0.99 | HDAC1 (0.81) | HDAC1HDAC2HDAC8EP300ERBB2 | |
| SCHEMBL805264 | 0.99 | HDAC1 (0.81) | HDAC1HDAC2HDAC8EP300ERBB2 | |
| SCHEMBL805278 | 0.99 | HDAC1 (0.81) | HDAC1HDAC2HDAC8EP300ERBB2 | |
| SCHEMBL13774347 | 0.99 | HDAC1 (0.81) | HDAC1HDAC2HDAC8EP300ERBB2 | |
| SCHEMBL16888574 | 0.98 | HDAC1 (0.82) | HDAC1HDAC2HDAC8EP300ERBB2 | |
| SCHEMBL805243 | 0.98 | HDAC1 (0.82) | HDAC1HDAC2HDAC8EP300ERBB2 | |
| SCHEMBL805241 | 0.98 | HDAC1 (0.82) | HDAC1HDAC2HDAC8EP300ERBB2 | |
| SCHEMBL24549898 | 0.98 | HDAC1 (0.81) | HDAC1HDAC2HDAC8EP300ERBB2 | |
| SCHEMBL805244 | 0.98 | HDAC1 (0.81) | HDAC1HDAC2HDAC8EP300ERBB2 | |
| SCHEMBL805245 | 0.98 | HDAC1 (0.81) | HDAC1HDAC2HDAC8EP300ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071628-A1 | TOPICAL THERAPEUTIC AGENT FOR OPHTHALMIC DISEASES COMPRISING COMPOUND CAPABLE OF BINDING SPECIFICALLY TO DNA SEQUENCE | NIHON UNIVERSITY (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071628-A1 | TOPICAL THERAPEUTIC AGENT FOR OPHTHALMIC DISEASES COMPRISING COMPOUND CAPABLE OF BINDING SPECIFICALLY TO DNA SEQUENCE | POLH, POLB, POLK | HDAC1 400/4885HDAC2 742/4885HDAC8 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.